| Description | DOTMA (N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium) is a tetra-methylated DOTA analogue. DOTMA is a cationic lipid and can be used as a non-viral vector for gene therapy. It has been used as a component in liposomes that can be used to encapsulate siRNA, microRNAs, and oligonucleotides and for gene transfection in vitro. It exhibits effective in vitro and in vivo gene transfection. DOTMA induces a positive charge on the liposomes and thus promotes efficient liposome- cell membrane interaction. |
| Synonyms | Trimethyl[2,3-(dioleyloxy)propyl]ammonium Chloride, N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium |
| molecular weight | 670.58 |
| Molecular formula | C42H84ClNO2 |
| CAS | 104872-42-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 45 mg/mL (67.1 mM), Sonication and heating to 60℃ are recommended. |
| References | 1. Aime S, et al. Properties, solution state behavior, and crystal structures of chelates of DOTMA. Inorg Chem. 2011;50(17):7955-7965. 2. Bhavsar D, et al. Translational siRNA therapeutics using liposomal carriers: prospects & challenges. Curr Gene Ther. 2012;12(4):315-332. 3. Ren T, et al. Structural basis of DOTMA for its high intravenous transfection activity in mouse. Gene Ther. 2000;7(9):764-768. |